Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection
- 31 October 1992
- journal article
- clinical trial
- Published by Elsevier in The Journal of Pediatrics
- Vol. 121 (4) , 627-633
- https://doi.org/10.1016/s0022-3476(05)81161-8
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Recombinant Soluble CD4 Therapy in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related ComplexAnnals of Internal Medicine, 1990
- Synergistic Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication In Vitro by Recombinant Soluble CD4 and 3'-Azido-3'-DeoxythymidineThe Journal of Infectious Diseases, 1989
- Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cellsNature, 1989
- The CD4 antigen: Physiological ligand and HIV receptorCell, 1988
- A soluble CD4 protein selectively inhibits HIV replication and syncytium formationNature, 1988
- Soluble CD4 molecules neutralize human immunodeficiency virus type 1Nature, 1988
- soluble form of CD4 (T4) protein inhibits AIDS virus infectionNature, 1988
- HIV infection is blocked in vitro by recombinant soluble CD4Nature, 1988
- Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 AntigenScience, 1987
- The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature, 1984